Resonance Health Ltd (ASX: RHT) has released an investor strategy day presentation, available for review on our website. The presentation highlights our strong revenue growth, diversified revenue streams, and dedication to scientific rigor, with a focus on providing high-quality quantitative assessments essential in managing diseases and drug development.

Our SaMD products, including FerriScan® and FerriSmart®, are regulatory cleared and internationally recognized for their accuracy in assessing liver iron concentration and fat. We also offer services in medical imaging analysis, clinical trials, and site management operations.

We invite investors to join a live webcast and Q&A session hosted by our leadership team. For further information, contact our Chief Executive Officer Andrew Harrison.

As we move forward, we are focused on expanding into new therapeutic areas, increasing our customer base, and improving operational efficiencies through technology investments. This strategic growth plan positions us for success, with a target EBITDA margin of approximately 25% and a revenue guidance of around $17 million for FY26.

If you have any questions or would like more information, please visit our website or reach out to us directly. We look forward to engaging with our stakeholders and sharing our progress.